Analysts Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Target Price at $43.20

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $43.20.

Separately, HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a report on Tuesday, September 17th.

Akero Therapeutics Price Performance

NASDAQ:AKRO opened at $34.45 on Wednesday. The company has a quick ratio of 24.89, a current ratio of 24.89 and a debt-to-equity ratio of 0.04. Akero Therapeutics has a 12-month low of $13.39 and a 12-month high of $37.00. The stock’s 50 day moving average price is $29.02 and its two-hundred day moving average price is $25.21. The firm has a market capitalization of $2.39 billion, a price-to-earnings ratio of -10.10 and a beta of -0.26.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings data on Friday, August 9th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. On average, analysts anticipate that Akero Therapeutics will post -3.64 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Catriona Yale sold 15,485 shares of Akero Therapeutics stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $32.62, for a total value of $505,120.70. Following the completion of the sale, the insider now directly owns 74,158 shares in the company, valued at approximately $2,419,033.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Akero Therapeutics news, CEO Andrew Cheng sold 108,366 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $31.73, for a total transaction of $3,438,453.18. Following the sale, the chief executive officer now directly owns 605,417 shares in the company, valued at $19,209,881.41. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Catriona Yale sold 15,485 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $32.62, for a total transaction of $505,120.70. Following the completion of the transaction, the insider now directly owns 74,158 shares in the company, valued at approximately $2,419,033.96. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 428,397 shares of company stock valued at $12,997,971. 7.94% of the stock is owned by company insiders.

Institutional Trading of Akero Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its stake in Akero Therapeutics by 2,366.0% in the first quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock valued at $31,000 after buying an additional 1,183 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Akero Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock valued at $71,000 after purchasing an additional 446 shares during the last quarter. Eastern Bank bought a new stake in shares of Akero Therapeutics during the 3rd quarter valued at approximately $100,000. Headlands Technologies LLC increased its position in Akero Therapeutics by 253.5% during the 1st quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock worth $107,000 after purchasing an additional 3,024 shares in the last quarter. Finally, Ameritas Investment Partners Inc. boosted its position in Akero Therapeutics by 20.0% in the first quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock valued at $156,000 after buying an additional 1,030 shares in the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.